Prasinezumab is a Monoclonal Antibody owned by Prothena Corp, and is involved in 5 clinical trials, of which 4 were completed, and 1 is ongoing.
Prasinezumab is an alpha-synuclein monoclonal antibody. Alpha-synuclein normally in an unstructured soluble form found almost exclusively in the nucleus of brain neurons. Alpha-synuclein is involved in neuronal plasticity and could act as a molecular chaperone. In synucleinopathies, the synuclein protein misfolds and aggregates to form insoluble fibrils that contribute to the pathology of the disease. Antibodies targeting alpha-synuclein might slow down or reduce the neurodegeneration associated with synuclein misfolding and/or transmission.
The revenue for Prasinezumab is expected to reach a total of $346m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Prasinezumab NPV Report.
Prasinezumab is under development for the treatment of Parkinson’s disease (PD) and other synucleinopathies. It is administered through intravenous route as an infusion. The drug candidate is a monoclonal antibody targeting alpha-synuclein. It is a new molecular entity (NME).
F. Hoffmann-La Roche Overview
F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, commercial laboratories, healthcare professionals, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.
The company reported revenues of (Swiss Francs) CHF62,801 million for the fiscal year ended December 2021 (FY2021), an increase of 7.7% over FY2020. In FY2021, the company’s operating margin was 28.9%, compared to an operating margin of 31.8% in FY2020. In FY2021, the company recorded a net margin of 22.2%, compared to a net margin of 24.5% in FY2020.
Quick View – Prasinezumab
|Highest Development Stage|